NewAmsterdam Pharma Company (NAMS) Revenue & Revenue Breakdown
NewAmsterdam Pharma Company Revenue Highlights
Latest Revenue (Y)
$14.09M
Latest Revenue (Q)
$1.40M
Main Segment (Y)
License Revenue
NewAmsterdam Pharma Company Revenue by Period
NewAmsterdam Pharma Company Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $14.09M | -85.55% |
| 2022-12-31 | $97.50M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | - |
NewAmsterdam Pharma Company generated $14.09M in revenue during NA 2023, up -85.55% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
NewAmsterdam Pharma Company Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $1.40M | -20.51% |
| 2023-06-30 | $1.76M | -79.58% |
| 2023-03-31 | $8.63M | -91.15% |
| 2022-12-31 | $97.50M | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
NewAmsterdam Pharma Company generated $1.40M in revenue during Q1 2024, up -20.51% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
NewAmsterdam Pharma Company Revenue Breakdown
NewAmsterdam Pharma Company Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 |
|---|---|
| License Revenue | $97.50M |
NewAmsterdam Pharma Company's latest annual revenue breakdown by segment (product or service), as of Dec 22: License Revenue (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 23 |
|---|---|
| License Revenue | $4.56M |
NewAmsterdam Pharma Company's latest quarterly revenue breakdown by segment (product or service), as of Jun 23: License Revenue (100.00%).
NewAmsterdam Pharma Company Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MRUS | Merus | $43.95M | $7.33M |
| IVA | Inventiva | $17.50M | $15.58M |
| NAMS | NewAmsterdam Pharma Company | $14.09M | $1.40M |
| JANX | Janux Therapeutics | $8.08M | $1.25M |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| PRTC | PureTech Health | $3.33M | $178.57K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| RZLT | Rezolute | - | - |
| CGEM | Cullinan Oncology | - | - |
| REPL | Replimune Group | - | - |
| CYT | Cyteir Therapeutics | - | - |
| ELYM | Eliem Therapeutics | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| CMPX | Compass Therapeutics | - | - |
| PEPG | PepGen | - | - |
NAMS Revenue FAQ
What is NewAmsterdam Pharma Company’s yearly revenue?
NewAmsterdam Pharma Company's yearly revenue for 2023 was $14.09M, representing a decrease of -85.55% compared to 2022. The company's yearly revenue for 2022 was $97.5M, representing an increase of 100.00% compared to 2021. NAMS's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is NewAmsterdam Pharma Company’s quarterly revenue?
NewAmsterdam Pharma Company's quarterly revenue for Q1 2024 was $1.4M, a -20.51% decrease from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022). The company's quarterly revenue for Q2 2023 was $1.76M, a -79.58% decrease from the previous quarter (Q1 2023), and a 0% increase year-over-year (Q2 2022). NAMS's quarterly revenue for Q1 2023 was $8.63M, a -91.15% decrease from the previous quarter (Q4 2022), and a 0% increase year-over-year (Q1 2022).
What is NewAmsterdam Pharma Company’s revenue growth rate?
NewAmsterdam Pharma Company's revenue growth rate for the last 3 years (2021-2023) was 0%
What are NewAmsterdam Pharma Company’s revenue streams?
NewAmsterdam Pharma Company's revenue streams in c 22 are License Revenue
What is NewAmsterdam Pharma Company’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of NewAmsterdam Pharma Company was License Revenue. This segment made a revenue of $97.5M, representing 100.00% of the company's total revenue.